Explore All AccessMedComm – Oncology : Impact Factor & More
eISSN: 2769-6448
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
MedComm – Oncology Journal Specifications
Indexed in the following public directories
DOAJ
| Overview | |
| Publisher | Wiley |
| Language | English |
| Article Processing Charges | USD 2800 |
| Publication Time | 15 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Sichuan International Medical Exchange & Promotion Association (SCIMEA) |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY |
| OA statement | Visit website |
View less
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers in MedComm – Oncology
Title not available
- 1 Dec 2024
- MedComm – Oncology
WNT2 blockade augments antitumor immunity by attenuating myeloid‐derived suppressor cells in colorectal cancer
- 1 Dec 2024
- MedComm – Oncology
Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients
- 24 Nov 2024
- MedComm – Oncology
Targeting LAG‐3 restores CD8<sup>+</sup> T cell effector function through CD94/NKG2‐Qa‐1b signaling
- 24 Nov 2024
- MedComm – Oncology
Immunotherapy for gastric cancer: Advances and challenges
- 4 Nov 2024
- MedComm – Oncology
Nanoparticle‐encapsuled celastrol‐Fe(III): “Single‐edged sword” for tumor therapy featuring microenvironment‐dependent toxicity
- 28 Oct 2024
- MedComm – Oncology
Title not available
- 1 Dec 2024
- MedComm – Oncology
WNT2 blockade augments antitumor immunity by attenuating myeloid‐derived suppressor cells in colorectal cancer
- 1 Dec 2024
- MedComm – Oncology
Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients
- 24 Nov 2024
- MedComm – Oncology
Targeting LAG‐3 restores CD8<sup>+</sup> T cell effector function through CD94/NKG2‐Qa‐1b signaling
- 24 Nov 2024
- MedComm – Oncology
Immunotherapy for gastric cancer: Advances and challenges
- 4 Nov 2024
- MedComm – Oncology
Nanoparticle‐encapsuled celastrol‐Fe(III): “Single‐edged sword” for tumor therapy featuring microenvironment‐dependent toxicity
- 28 Oct 2024
- MedComm – Oncology
FAQs on MedComm – Oncology
How many articles did MedComm – Oncology publish last year? 
In 2023, MedComm – Oncology publsihed 46 articles.
Who is the publisher of MedComm – Oncology?
Wiley is the publisher of MedComm – Oncology.
